Year archive

BioPorto — 2024 filings

All 34 regulatory filings released by BioPorto (BIOPOR) in 2024, sourced directly from the official regulator.

34 Filings

2024 Period

2024 filings (34)

Filing	Released	Lang
Board/Management Information 2024 Board/Management Information	2024-12-16	English
Board/Management Information 2024 Board/Management Information	2024-12-16	English
Regulatory Filings 2024 Regulatory Filings	2024-10-29	Danish
Regulatory Filings 2024 Regulatory Filings	2024-10-29	English
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital Regulatory Filings	2024-10-29	Danish
First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital Regulatory Filings	2024-10-29	English
Regulatory Filings 2024 Regulatory Filings	2024-10-28	English
Regulatory Filings 2024 Regulatory Filings	2024-10-28	Danish
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests Regulatory Filings	2024-10-28	Danish
BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests Regulatory Filings	2024-10-28	Danish
Interim / Quarterly Report 2024 Interim / Quarterly Report H1 2024	2024-08-15	English
BioPorto Announces Interim Results and Business Update for the Second Quarter and Six Months of Fiscal 2024 Report Publication Announcement H1 2024	2024-08-15	English
Director's Dealing 2024 Director's Dealing	2024-06-24	English
Managers’ transactions Director's Dealing	2024-06-24	Danish
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-24	English
Changes of number of shares and votes in BioPorto A/S Share Issue/Capital Change	2024-06-24	English
Capital/Financing Update 2024 Capital/Financing Update	2024-06-17	English
BioPorto A/S initiates a private placement of 50,000,000 new shares at market price. Capital/Financing Update	2024-06-17	English
Annual Report (ESEF) 2023 Annual Report (ESEF) FY 2023	2024-04-04	English
Earnings Release 2023 Earnings Release FY 2023	2024-04-04	English
Correction: BioPorto Announces Annual Results for 2023 Annual Report FY 2023	2024-04-04	English
Correction: BioPorto Announces Annual Results for 2023 Remuneration Information	2024-04-04	English
Annual Report (ESEF) 2023 Annual Report (ESEF) FY 2023	2024-04-04	English
Earnings Release 2023 Earnings Release FY 2023	2024-04-04	English
BioPorto Announces Annual Results for 2023 Annual Report FY 2023	2024-04-04	English
BioPorto Announces Annual Results for 2023 Remuneration Information	2024-04-04	English
Board/Management Information 2024 Board/Management Information	2024-04-02	English
BioPorto appoints Peter Mørch Eriksen as permanent Group Chief Executive Officer Board/Management Information	2024-04-02	English
Earnings Release 2023 Earnings Release FY 2023	2024-02-22	English
BioPorto announces preliminary results for 2023 and provides strategic update for the period 2024-2026 Earnings Release FY 2023	2024-02-22	English
Regulatory Filings 2024 Regulatory Filings	2024-02-20	English
Roche Diagnostics and BioPorto expand collaboration Regulatory Filings	2024-02-20	English
Board/Management Information 2024 Board/Management Information	2024-01-09	English
BioPorto implements changes to the Executive Management. Board/Management Information	2024-01-09	English

Filings by year

2026 25 filings
2025 63 filings
2024 34 filings
2023 24 filings
2022 24 filings
2021 29 filings
2020 23 filings
2019 37 filings
2018 28 filings
2017 43 filings
2016 104 filings
2015 36 filings
2014 23 filings
2013 78 filings
2012 56 filings
2011 43 filings
2010 28 filings
2009 46 filings
2008 36 filings
2007 8 filings